Hemispherx Biopharma Inc. said it is continuing to make progress on its new drug application (NDA) for Ampligen, the Philadelphia company's experimental treatment for chronic fatigue syndrome. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

 

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

View the full article